Changes in fecal short‐chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome

Short‐chain fatty acids (SCFAs) may play a role in the pathophysiology of irritable bowel syndrome (IBS). This study analyzed fecal SCFAs after performing fecal microbiota transplantation (FMT) in the IBS patients who were included in our previous study of the efficacy of FMT.

[1]  E. Savarino,et al.  Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease , 2020, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[2]  O. Gilja,et al.  Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study , 2019, Gut.

[3]  A. Farmer,et al.  Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[4]  T. Hausken,et al.  Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS) , 2019, Neuropeptides.

[5]  T. Hausken,et al.  Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones , 2019, Nutrients.

[6]  L. Duan,et al.  Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome , 2019, Medicine.

[7]  L. Duan,et al.  Beneficial effect of butyrate‐producing Lachnospiraceae on stress‐induced visceral hypersensitivity in rats , 2018, Journal of gastroenterology and hepatology.

[8]  J. de Vries,et al.  The Fatigue Assessment Scale: quality and availability in sarcoidosis and other diseases , 2018, Current opinion in pulmonary medicine.

[9]  M. Bellini,et al.  Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial , 2018, United European gastroenterology journal.

[10]  Wei Zhang,et al.  Butyrate promotes visceral hypersensitivity in an IBS‐like model via enteric glial cell‐derived nerve growth factor , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[11]  M. El-Salhy,et al.  Fecal microbiota transplantation for managing irritable bowel syndrome , 2018, Expert review of gastroenterology & hepatology.

[12]  H. Tilg,et al.  European consensus conference on faecal microbiota transplantation in clinical practice , 2017, Gut.

[13]  M. Vatn,et al.  Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD , 2015, Alimentary pharmacology & therapeutics.

[14]  J. Walkowiak,et al.  Butyric acid in irritable bowel syndrome , 2013, Przeglad gastroenterologiczny.

[15]  R. Marciniak,et al.  Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[16]  D. Drossman,et al.  Quality of life measures in irritable bowel syndrome , 2010, Expert review of gastroenterology & hepatology.

[17]  P. de Coppet,et al.  Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. , 2010, Gastroenterology.

[18]  A. Bast,et al.  Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. , 2009, Clinical nutrition.

[19]  R. Tulley,et al.  Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. , 2008, American journal of physiology. Endocrinology and metabolism.

[20]  A. Roalfe,et al.  Evaluation of the Birmingham IBS symptom questionnaire , 2008, BMC gastroenterology.

[21]  D. Jonkers,et al.  Review article: the role of butyrate on colonic function , 2007, Alimentary pharmacology & therapeutics.

[22]  T. Iwanaga,et al.  Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine , 2006, Cell and Tissue Research.

[23]  A. Berstad,et al.  Quality of Life in Patients with Subjective Food Hypersensitivity: Applicability of the 10-Item Short Form of the Nepean Dyspepsia Index , 2004, Digestive Diseases and Sciences.

[24]  D. Drossman,et al.  Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire , 2000, American Journal of Gastroenterology.

[25]  S. Lewis,et al.  Increasing butyrate concentration in the distal colon by accelerating intestinal transit , 1997, Gut.

[26]  P. Whorwell,et al.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress , 1997, Alimentary pharmacology & therapeutics.

[27]  A. Bjørneklett,et al.  Short-chain fatty acids in the normal human feces. , 1984, Scandinavian journal of gastroenterology.

[28]  B. M. Byrne,et al.  Pretreatment methods prior to gaschromatographic analysis of volatile fatty acids from faecal samples. , 1977, Clinica chimica acta; international journal of clinical chemistry.